Login to Your Account

Closing in on a $100B Market Cap

Biotech Sector Continues Its Torrid Pace in Third Quarter

By Peter Winter

Monday, September 30, 2013

It wasn’t all that long ago that Amgen Inc. and Genentech Inc., prior to its acquisition by Basel, Switzerland-based Roche AG, both commanded impressive $100 billion market caps. Since that milestone was reached, valuations of the public biotech companies have declined, until recently that is.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription